Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 25, 2007 Brian Orelli	Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row.
The Motley Fool October 25, 2007 Brian Orelli	Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter.
The Motley Fool October 24, 2007 Brian Orelli	Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down.
The Motley Fool July 26, 2007 Brian Orelli	Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit.
The Motley Fool April 25, 2008 Brian Orelli	Affymetrix Learns About Inertia Slower sales of its older chips drag down growth.
BusinessWeek February 20, 2006 Gene G. Marcial	Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it.
Bio-IT World Jul/Aug 2006 Deb Janssen	Managing the Microarray Data Mountain Genomic studies often involve thousands of samples and require hundreds of thousands of assays per sample. Microarray manufacturers are scurrying to satisfy researcher demands for increased array density, sample number, and content flexibility.
The Motley Fool August 6, 2008 Brian Orelli	Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
Bio-IT World October 2006 Kevin Davies	Microarray Platforms Shine DNA microarrays from the leading commercial sources are more reliably consistent than previously suspected, according to a new study.
Wired June 2000 Brian Alexander	Biopoly Money Patents and strong-arm tactics are helping make Affymetrix the Intel of biochips. Along the way, Affy wants to turn DNA into a proprietary system.
The Motley Fool April 24, 2008 Brian Orelli	Illumina Ignites This biochip maker is on fire.
Bio-IT World August 15, 2005 Kevin Davies	TGen's Discovery Pipeline in the Desert At the Translational Genomics Research Institute, researchers have developed an industrial-style informatics strategy and discovery infrastructure that has pinpointed some 25 disease genes in the past 24 months, many of which are pending identification.
The Motley Fool January 11, 2008 Brian Orelli	Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix.
The Motley Fool August 7, 2006 Stephen D. Simpson	Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors.
Bio-IT World July 2005 Johan Bostrom	Affymetrix to Acquire ParAllele The companies have been working together for the past two years, with Affymetrix using ParAllele's assay technology with the Affymetrix GeneChip technology. Affymetrix expects to strengthen its assay R&D capabilities and add knowledge in specific assay capabilities through the acquisition.
The Motley Fool October 28, 2009 Brian Orelli	Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.
The Motley Fool January 28, 2005 Karl Thiel	Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005.
The Motley Fool February 6, 2008 Brian Orelli	Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward?
Bio-IT World February 2007 Robert M. Frederickson	Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform.
The Motley Fool March 18, 2008 Brian Orelli	The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?
The Motley Fool April 24, 2006 John Bluis	Affymetrix Gets Chipped Again The woes continue for Affymetrix, the leading provider of high-density microarray products. Investors must decide if this is a management issue -- as indeed it appears to be.
Bio-IT World July 14, 2004 Malorye A. Branca	The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint
Managed Care August 2004 Thomas Morrow	10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans.
The Motley Fool January 31, 2006 John Bluis	Affymetrix: Far, Far Array Investors who enjoy companies that are consistent with guidance may have some interest in this company that provides tools for use in genomics-related research. Unfortunately, this year the consistency was in reporting disappointing results.
The Motley Fool October 24, 2008 Brian Orelli	Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell.
The Motley Fool July 22, 2009 Brian Orelli	Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
The Motley Fool April 27, 2011 Brian Orelli	Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby.
The Motley Fool August 16, 2007 Brian Orelli	More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too.
The Motley Fool July 25, 2008 Brian Orelli	Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out.
Salon.com May 1, 2000 Arthur Allen	Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic.
The Motley Fool February 8, 2010 Brian Orelli	An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement.
The Motley Fool July 24, 2008 Brian Orelli	Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth.
PC Magazine November 5, 2003	Bits & Bytes The entire human genome now exists on a chip... On the average, a typical corporate user receives 81 e-mails and sends 29 messages per day... Online retail sales in the U.S. have jumped in 2003...
The Motley Fool February 4, 2009 Brian Orelli	43% Growth! Yee-Haw! Illumina rocks another quarter.
The Motley Fool September 28, 2005 Stephen D. Simpson	Affymetrix Stumbles Again Though the company was one of the only genomics plays to escape the bubble with a real business and a solid market cap, Affymetrix's stock seemed poised to take a serious hit Wednesday for the second time in about three months.
PC World February 1, 2002 Kuriko Miyake	Olympus Unveils DNA Computer Rather than relying on a microprocessor, computer runs on reactions between fragments of DNA...
The Motley Fool November 12, 2008 Brian Orelli	Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash.
Chemistry World January 8, 2013 Andrew Turley	Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities.
The Motley Fool October 22, 2008 Jim Mueller	Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated.
BusinessWeek April 25, 2005 Gene G. Marcial	Affymetrix: A Lab Boost The GeneChip can reduce the risk of adverse reactions to drugs by checking the recipient's DNA against the drug's profile. Some people are optimistic about the company's stock.
The Motley Fool July 28, 2010 Brian Orelli	Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.
Technology Research News June 16, 2004	Genes Automate DNA Machines Researchers have taken a step toward automating nanomachines with a method that allows instructions for a DNA-based machine to be contained in a gene, or another stretch of DNA.
Bio-IT World June 2006	News Blast Spectral Spend... Nanoscale News... Testmakers...
The Motley Fool January 3, 2012 Alex Planes	Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on.
Salon.com December 19, 2000 Carolyn McConnell	"The Century of the Gene" by Evelyn Fox Keller A new book argues that there may be no such thing as a gene. At least, it has proved very difficult to isolate a discrete physical item that can do the work our notion of the gene does...